ATE433988T1 - Phosphoramidatderivate - Google Patents

Phosphoramidatderivate

Info

Publication number
ATE433988T1
ATE433988T1 AT05701927T AT05701927T ATE433988T1 AT E433988 T1 ATE433988 T1 AT E433988T1 AT 05701927 T AT05701927 T AT 05701927T AT 05701927 T AT05701927 T AT 05701927T AT E433988 T1 ATE433988 T1 AT E433988T1
Authority
AT
Austria
Prior art keywords
phosphoramidate derivatives
ester
present
provides
phosphoramidate
Prior art date
Application number
AT05701927T
Other languages
English (en)
Inventor
Christopher Mcguigan
Antonella Carangio
Bruce Caterson
Clare Hughes
Clare Louise Curtis
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff filed Critical Univ Cardiff
Application granted granted Critical
Publication of ATE433988T1 publication Critical patent/ATE433988T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04Phosphates; Phosphites; Polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Luminescent Compositions (AREA)
AT05701927T 2004-01-19 2005-01-18 Phosphoramidatderivate ATE433988T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0401088.0A GB0401088D0 (en) 2004-01-19 2004-01-19 Phosphoramidate derivatives
PCT/GB2005/000161 WO2005070944A1 (en) 2004-01-19 2005-01-18 Phosphoramidate derivatives

Publications (1)

Publication Number Publication Date
ATE433988T1 true ATE433988T1 (de) 2009-07-15

Family

ID=31726385

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05701927T ATE433988T1 (de) 2004-01-19 2005-01-18 Phosphoramidatderivate

Country Status (9)

Country Link
US (1) US8119779B2 (de)
EP (1) EP1709056B1 (de)
JP (1) JP5137403B2 (de)
AT (1) ATE433988T1 (de)
DE (1) DE602005014936D1 (de)
DK (1) DK1709056T3 (de)
ES (1) ES2328495T3 (de)
GB (1) GB0401088D0 (de)
WO (1) WO2005070944A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
MXPA05005192A (es) 2002-11-15 2005-09-08 Idenix Cayman Ltd Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae.
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
EP2471802A1 (de) 2010-12-27 2012-07-04 Bioiberica, S.A. Phosphoramidate aus Monosacchariden
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
GB201111779D0 (en) 2011-07-08 2011-08-24 Univ Cardiff Chemical compounds
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのd−アミノ酸化合物
CA2871547C (en) 2012-05-25 2021-05-25 Janssen R&D Ireland Uracyl spirooxetane nucleosides
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
AU2013329521B2 (en) 2012-10-08 2018-04-19 Centre National De La Recherche Scientifique 2'-chloro nucleoside analogs for HCV infection
EP2909222B1 (de) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-verbrückten nukleoside für hcv-infektion
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
EP3027636B1 (de) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotide of halogenierte pyrimidine verbindungen für leber krankheiten
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
US9828410B2 (en) 2015-03-06 2017-11-28 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP4088725A1 (de) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. 2'-substituierte-n6-substituierte purinnukleotide zur behandlung von picornaviridae
WO2019118486A1 (en) * 2017-12-11 2019-06-20 Cerecor Inc. Monosaccharide phosphoramidate prodrugs
JP7147781B2 (ja) 2018-06-19 2022-10-05 住友ゴム工業株式会社 重荷重用空気入りタイヤ
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059272A1 (en) * 1990-04-12 1991-10-13 Akira Hasegawa 4,6-0-hydroxyphosphoryl-glucosamine derivatives
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
ATE212661T1 (de) * 1998-01-23 2002-02-15 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
US6030957A (en) 1998-06-29 2000-02-29 Wayne Hughes Institute Aryl phosphate derivatives of d4T having anti-HIV activity
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
CN1346360A (zh) 1999-02-12 2002-04-24 葛兰素集团有限公司 作为抗病毒剂的(1r,顺式)-4-(6-氨基-9h-嘌呤-9-基)-2-环戊烯-1-甲醇的氨基磷酸酯及一二和三磷酸酯
CA2317305A1 (en) * 2000-08-29 2002-02-28 Tassos P. Anastassiades Method of enhancing chondrocyte cell growth and glycosaminoglycan production
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives

Also Published As

Publication number Publication date
DE602005014936D1 (en) 2009-07-30
WO2005070944A1 (en) 2005-08-04
DK1709056T3 (da) 2009-08-10
US20070275910A1 (en) 2007-11-29
GB0401088D0 (en) 2004-02-18
EP1709056A1 (de) 2006-10-11
JP2007518734A (ja) 2007-07-12
EP1709056B1 (de) 2009-06-17
JP5137403B2 (ja) 2013-02-06
ES2328495T3 (es) 2009-11-13
US8119779B2 (en) 2012-02-21

Similar Documents

Publication Publication Date Title
ATE433988T1 (de) Phosphoramidatderivate
AR110313A2 (es) Derivados de tiazol-2-il-pirrolidina
HRP20090113T3 (en) C-aryl glucoside sglt2 inhibitors and method for their production
TNSN08191A1 (en) Kinase inhibitors
RS52274B (en) UNIT DIARYLHIDANTOIN
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
GB0521508D0 (en) Organic compounds
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
TW200728307A (en) Novel spirochromanone derivatives
TW200508228A (en) Biaryl heterocyclic compounds and methods of making and using the same
RS52323B (en) 2'-FLUORO-2'-DEOKSITETRAHIDROURIDINI KAO INHIBITORI CITIDIN DEAMINAZE
AU2006304874A8 (en) Pyrimidinones as casein kinase II (CK2) modulators
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2007117465A3 (en) Indazole compounds
RS52874B (en) THYOPHEN ANALYSIS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
WO2006047528A3 (en) Pyrazolobenzamides and derivatives as factor xa inhibitors
DE602007011902D1 (de) Spiroindolinon-derivate
WO2007084728A3 (en) 2-imino-benzimidazoles
GT200300087A (es) 2-(2,6-diclorofenil)-diarilimidazoles
WO2007023342A3 (en) Process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof
EP1831239B8 (de) Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-carbonsäure gamma-lacton und schlüsselzwischenprodukte für dieses verfahren
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
NO20084543L (no) Benzimidazolderivater
WO2006083841A3 (en) Therapeutic esters

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties